Ann: Enforceable Undertaking, page-6

Abdm,
With respect I disagree, this current Board are showing real signs of working hard to achieve real shareholder value. That's not necessarily an implied criticism of previous directors either, they did what they thought they had to do to stay afloat and commercialise the tech.
Today we are in a new space. Of course investing in NSP still represents putting money into a "speculative bio tech microcap" It should go without saying that if you are in this space you need to be prepared to lose your stake. Of course it's high risk...the higher the risk the higher the potential returns, that's the very rationale for investing some funds in spec stocks isn't it? If (as looks increasingly likely) our company is successful we will all be richly rewarded. Accordingly this is not a stock for daytraders or get rich quick merchants. Like most bio tech opportunities it requires a long game and that in turn requires patience. I've been following (and putting my hard earned money into) NSP since 2008 and have steadily increased my stake. Currently I am feeling much more confident about this stock providing a fitting return. But don't take my word for it, our Chairman who has earned her credibility in the real commercial world says to us in part:

"We expect the present book value of $3.8m of the PrIME asset on NuSep’s balance sheet
will substantially increase over the time, which will have a positive impact on NuSep’s
net asset position. Also, as we grow the SpermSep business, its value should also
improve and add to a more positive net asset position."

I rest my case, I see the SP moving steadily north from here over the next two to three years.
Kind regards,